Antibiotics for irritable bowel syndrome: Rationale and current evidence

Current Gastroenterology Reports

Volumn 14, Issue 5, 2012, Pages 439-445

  Sachdev, Amit H ^a   Pimentel, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Irritable bowel syndrome; Postinfectious irritable bowel syndrome; Small intestinal bacterial overgrowth

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CLAVULANIC ACID; DOXYCYCLINE; METRONIDAZOLE; NEOMYCIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; TETRACYCLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADAPTIVE IMMUNITY; ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BACTERIUM CULTURE; CAMPYLOBACTER JEJUNI; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG RETENTION; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE INFECTION; IRRITABLE COLON; KLEBSIELLA PNEUMONIAE; MUCOSAL IMMUNITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEUS MIRABILIS; REVIEW; SMALL INTESTINAL BACTERIAL OVERGROWTH; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BLIND LOOP SYNDROME; HUMANS; INTESTINE, SMALL; IRRITABLE BOWEL SYNDROME;

EID: 84870525476     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0284-2     Document Type: Review

References (100)

1. Drossman DA, Sandler RS, McKee DC, et al. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology. 1982;83(3):529-34.
2. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology. 1980;79(2):283-8.
3. Thompson WG. The functional gastrointestinal bowel disorders. In: Drossman DA, editor. The functional gastrointestinal disorders. Boston: Little, Brown; 1994. p. 117-34.
4. Whitehead WE. Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. Am J Med. 1999;107(5A):33S-40S.
5. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45 Suppl 2:II43-7.
6. Pimentel M, Hwang L, Melmed GY, et al. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: The LA/IBS diagnostic strategy. Dig Dis Sci. 2010;55(1):145-9.
7. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
8. Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):237-41.
9. Guidelines-Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):307-12
10. Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology. 1984;87(1):1-7.
11. Mertz HR. Irritable bowel syndrome. N Engl J Med. 2003;349 (22):2136-46.
12. Ringel Y, Williams RE, Kalilani L, et al. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(1):68-72. quiz 3.
13. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci. 1993;38(10):1773-82.
14. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig Dis Sci. 1993;38(10):1761-72.
15. Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 1998;228(2):188-93.
16. Pimentel M, Soffer EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47 (12):2639-43.
17. Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000;118(5):842-8.
18. Manabe N, Tanaka T, Hata J, et al. Pathophysiology underlying irritable bowel syndrome-from the viewpoint of dysfunction of autonomic nervous system activity. J Smooth Muscle Res. 2009;45(1):15-23.
19. Whitehead WE, Crowell MD, Robinson JC, et al. Effects of stressful life events on bowel symptoms: Subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut. 1992;33(6):825-30.
20. Levy RL, Cain KC, Jarrett M, et al. The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome. J Behav Med. 1997;20(2):177-93.
21. Blanchard EB, Lackner JM, Jaccard J, et al. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res. 2008;64(2):119-28.
22. Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol. 2010;44 (10):672-5.
23. Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802-8. Provided the first conclusive direct evidence for SIBO in IBS i.e. evidence based on culture of the small bowel rather than breath testing.
24. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: Relationship with Irritable Bowel Syndrome. Dig Dis Sci. 2012
25. Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279-86.
26. Shah ED, Basseri RJ, Chong K, et al. Abnormal breath testing in IBS: A meta-analysis. Dig Dis Sci. 2010;55(9):2441-9.
27. Quigley EM. New perspectives on the role of the intestinal flora in health and disease. J Gastrointestin Liver Dis. 2006;15(2):109-10.
28. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355-9.
29. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449(7164):804-10.
30. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503-6.
31. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412-9.
32. Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: A prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(11-12):1157- 60.
33. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: A retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52(1):89-95.
34. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: Clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139-42. Important early study demonstrating SIBO in IBS pa#ents and the efficacy of antibiotic (rifaximin) treatment in allevia#ng symptoms.
35. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized doubleblind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101 (2):326-33.
36. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32. Describes two large phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2) which showed that treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms in patients who had IBS without constipation.
37. Lin HC, Pimentel M. Bacterial concepts in irritable bowel syndrome. Rev Gastroenterol Disord. 2005;5 Suppl 3:S3-9.
38. Basseri RJ, Weitsman S, Barlow GM, et al. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (NY). 2011;7(7):455-93.
39. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996;4(11):430-5.
40. Macfarlane S, Macfarlane GT. Bacterial diversity in the human gut. Adv Appl Microbiol. 2004;54:261-89.
41. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915-20.
42. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688-93.
43. Frank DN, St Amand AL, Feldman RA, et al. Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780-5.
44. Swidsinski A, Loening-Baucke V, Lochs H, et al. Spatial organization of bacterial flora in normal and inflamed intestine: A fluorescence in situ hybridization study in mice. World J Gastroenterol. 2005;11(8):1131-40.
45. Gorbach SL, Plaut AG, Nahas L, et al. Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology. 1967;53 (6):856-67.
46. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107-33.
47. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999;69(5):1035S-45S.
48. Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5(7):e177.
49. Pimentel M, Chang C. Inflammation and microflora. Gastroenterol Clin North Am. 2011;40(1):69-85.
50. Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859-904.
51. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther. 2011;130(2):202-12.
52. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691-701.
53. Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract. 2010;2010.
54. Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011;62:361-80.
55. Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20 Suppl 2:1-9.
56. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26-37.
57. McNeil NI. The contribution of the large intestine to energy supplies in man. Am J Clin Nutr. 1984;39(2):338-42.
58. Pimentel M. Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: Part 1. Am J Gastroenterol. 2010;105(4):718-21.
59. Mitsuoka T. Recent trends in research on intestinal flora. Bifido Microflora. 1982;1:3-24.
60. Toskes PP. Bacterial overgrowth of the gastrointestinal tract. Adv Intern Med. 1993;38:387-407.
61. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am. 2009;19(1):141-50. vii.
62. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133 (1):24-33.
63. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology. 1984;86(1):174-93.
64. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006;444 (7122):1022-3.
65. Pimentel M, Lezcano S. Irritable bowel syndrome: Bacterial overgrowth-what's known and what to do. Curr Treat Options Gastroenterol. 2007;10(4):328-37.
66. Pimentel M. The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions). Gut. 2008;57(9):1334-5. author reply 5.
67. King CE, Toskes PP. Small intestine bacterial overgrowth. Gastroenterology. 1979;76(5 Pt 1):1035-55.
68. Vantrappen G, Janssens J, Hellemans J, et al. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59 (6):1158-66.
69. Jee SR, Morales W, Low K, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol. 2010;16(29):3680-6.
70. Khoshini R, Dai SC, Lezcano S, et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443-54.
71. Sahakian AB, Jee SR, Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci. 2010;55(8):2135-43.
72. Kunkel D, Makhani MD, Chong K, et al. Methane on breath testing is associated with constipation: A systematic review and meta-analysis. Gastroenterology. 2010;138:S629.
73. Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55(3):297-303.
74. Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol. 2008;103(4):958-63.
75. Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98(2):302-9.
76. Youn YH, Park JS, Jahng JH, et al. Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome. Dig Dis Sci. 2011;56(7):2059-66.
77. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962-7.
78. Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53(4):982-9.
79. Tack J, Fried M, Houghton LA, et al. Systematic review: The efficacy of treatments for irritable bowel syndrome-a European perspective. Aliment Pharmacol Ther. 2006;24(2):183-205.
80. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study. Gut. 1998;42(1):42-6.
81. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161(14):1733-40.
82. Cash BD, Chey WD. Advances in the management of irritable bowel syndrome. Curr Gastroenterol Rep. 2003;5(6):468-75.
83. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15(10):1655-66.
84. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16(11):1877-88.
85. Drossman DA, Toner BB, Whitehead WE, et al. Cognitivebehavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19-31.
86. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14(1):23-34.
87. PimentelM, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med. 2006;145(8):557-63.
88. Lembo A, Zakko SF, Ferreira NL, et al. T1390 Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: Short term treatment leading to long term sustained response. Gastroenterology. 2008;134(4, Supplement 1):A-545.
89. Van Citters GW, Lin HC. Management of small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2005;7(4):317-20.
90. Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169-74.
91. Lamanna A, Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia. 1984;3(6):365-7.
92. Gerard L, Garey KW, DuPont HL. Rifaximin: A nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005;3(2):201-11.
93. Jiang ZD, DuPont HL. Rifaximin: In vitro and in vivo antibacterial activity-a review. Chemotherapy. 2005;51 Suppl 1:67-72.
94. Hoover WW, Gerlach EH, Hoban DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis. 1993;16(2):111-8.
95. Ripa S, Mignini F, Prenna M, et al. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp Clin Res. 1987;13(8):483-8.
96. Sierra JM, Navia MM, Vargas M, et al. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother. 2001;47(6):904-5.
97. Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14(5):551-6.
98. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dosefinding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22(1):31-5.
99. Pimentel M, Park S, Kane SV, et al. Rifaximin, a non-absorbable antibiotic improves the symptoms of irritable bowel syndrome: A randomized, double-blind, placebo-controlled study. Ann Intern Med. 2006;145:557-63.
100. Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci. 2011;56(7):2067-72. Demonstrated that for subjects with nonconstipated IBS, retreatment with rifaximin was successful up to five times with no significant reduction in benefit, or of duration of benefit, for successive retreatments.